Families Shoulder Majority of Costs Related to Dementia Care

This article originally appeared here.
Share this content:
Families Shoulder Majority of Costs Related to Dementia Care
Families Shoulder Majority of Costs Related to Dementia Care

THURSDAY, Aug. 17, 2017 (HealthDay News) -- Lifetime costs of care are substantially increased for individuals with dementia, according to a study published online Aug. 17 in the Journal of the American Geriatrics Society.

Eric Jutkowitz, Ph.D., from the School of Public Health at Brown University in Providence, R.I., and colleagues developed an evidence-based mathematical model to simulate disease progression for newly diagnosed dementia. The authors predicted costs from data-driven trajectories of cognition, function, and behavioral and psychological symptoms.

The researchers found that from the time of diagnosis, the discounted total lifetime cost of care was $321,780 for a person with dementia. Families incurred 70 percent of the total cost burden, while Medicaid and Medicare accounted for 14 and 16 percent, respectively. Over a lifetime, costs for a person with dementia were $184,500 greater than for someone without dementia (86 percent incurred by families). The total annual and net costs peaked at $89,000 and $72,400, respectively. A 10 percent reduction in functional decline or behavioral and psychological symptoms resulted in $3,880 and $680 lower lifetime costs than natural disease progression.

"Dementia substantially increases lifetime costs of care," the authors write. "Long-lasting, effective interventions are needed to support families because they incur the most dementia cost."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »